NEW YORK, Jan. 17, 2024 /PRNewswire/ -- The antimicrobial therapeutics market is expected to grow by USD 51.4 billion from 2022 to 2027. In addition, the momentum of the market will progress at a CAGR of 5.63% during the forecast period, according to Technavio Research. The market has been segmented by application (antiviral, antibacterial, antifungal, and antiparasitic), end-user (pharmacies, hospitals and clinics, and research and academic institutes), and geography (North America, Europe, Asia, and Rest of World (ROW)). North America accounts for 38% of the growth of the global market during the forecast period. The increasing prevalence of microbial diseases, particularly in the United States and Canada, is a significant driver of the North American market.
This report offers an up-to-date analysis of the current market scenario, the latest trends and drivers, and the overall market environment. Read the Free PDF Sample Report
Company Profile:
AbbVie Inc., Astellas Pharma Inc., Bavarian Nordic AS, Biocidium Biopharmaceuticals Inc., Bristol Myers Squibb Co., Cadila Pharmaceuticals Ltd., CSL Ltd., Emergent BioSolutions Inc., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Inovio Pharmaceuticals Inc., Johnson and Johnson Services Inc., Merck and Co. Inc., Mitsubishi Tanabe Pharma Corp., Novartis AG, Novavax Inc., Pfizer Inc., Sanofi SA, and Wockhardt Ltd.
AbbVie Inc.- The company conducts research and development, manufacturing, and commercialization, and offers innovative medicines and therapies globally. The company offers azactam injection which is used as medicine to treat symptoms of bacterial infections that occur in the blood and urinary tract.
To gain access to more company profiles available with Technavio, buy the report!
Antimicrobial Therapeutics Market: Segmentation Analysis
By Segment -
The market share growth by the antiviral segment is significant during the forecast period. The segment is fuelled by the increasing prevalence of viral infections including influenza, hepatitis, COVID-19, and HIV/AIDS.
Learn about the contribution of each segment summarized in concise infographics and thorough descriptions. View a Free PDF Sample Report
"Besides analyzing the current market scenario, our report examines historic data from 2017 to 2021"- Technavio
Antimicrobial Therapeutics Market: Driver & Trend:
- Initiatives from government agencies in the pharmaceutical industry
- Recent drug approvals and a robust pipeline
- Rising awareness about microbial diseases
The initiatives from government agencies in the pharmaceutical industry drive market growth. Several developed countries, such as the United States, Canada, the United Kingdom, Germany, France, Australia, and Japan, implement government insurance programs for medicines. These initiatives play a crucial role in supporting the treatment of patients with microbial infections, ensuring broader access to essential medications, and promoting public health in these nations.
The Antimicrobial Therapeutics Market faces multifaceted challenges encompassing Antibiotics, Antivirals, Antifungals, Antiparasitics, Antimicrobial Peptides, Vaccines, and more. Rising Antimicrobial Resistance complicates treatment efficacy, urging innovation in Drug Development and Combination Therapy. Additionally, issues like Antimicrobial Stewardship, Biofilms in Infections, and the emergence of Novel Antimicrobial Agents demand attention. Personalized Medicine, Immunotherapy, and Host-Targeted Therapies are gaining importance. Addressing Antimicrobial Drug Resistance Surveillance and developing Topical Antimicrobials become critical. The integration of Nanoparticles, Therapeutic Antibodies, and Probiotics, along with advancing Point-of-Care Diagnostics and exploring Pharmacokinetics, shapes the future. Navigating these challenges is vital for shaping Global Antimicrobial Therapeutics Market Trends amid the backdrop of Emerging Infectious Diseases.
Identify key trends, drivers, and challenges in the market. Download a sample to gain access to this information.
Related Reports:
The plasma fractionation market size is estimated to grow by USD 10.00 billion at a CAGR of 6.09% between 2023 and 2028.
The base editing market size is forecast to increase by USD 307.66 million, at a CAGR of 15.1% between 2023 and 2028.
What are the key data covered in this antimicrobial therapeutics market report?
- CAGR of the market during the forecast period
- Detailed information on factors that will drive the growth of the antimicrobial therapeutics market between 2022 and 2027.
- Precise estimation of the antimicrobial therapeutics market size and its contribution to the market in focus on the parent market
- Accurate predictions about upcoming trends and changes in consumer behavior
- Growth of the antimicrobial therapeutics market across North America, Europe, Asia, and ROW
- A thorough analysis of the market's competitive landscape and detailed information about companies
- Comprehensive analysis of factors that will challenge the growth of the antimicrobial therapeutics market players.
ToC:
Executive Summary
Market Landscape
Market Sizing
Historic Market Sizes
Five Forces Analysis
Market Segmentation by Application
Market Segmentation by End-user
Market Segmentation by Geography
Customer Landscape
Geographic Landscape
Drivers, Challenges, & Trends
Company Landscape
Company Analysis
Appendix
About Technavio
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com
SOURCE Technavio
![](https://rt.prnewswire.com/rt.gif?NewsItemId=CG12861&Transmission_Id=202401170035PR_NEWS_USPR_____CG12861&DateId=20240117)
Share this article